FAM181A

Across TCGA pan-cancer cohorts, FAM181A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM181A data layer compared with 15 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher FAM181A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM181A expression acts as an unfavorable survival marker.

SARC, LIHC, and UCEC are the cancer types where FAM181A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.032	0.861	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	OS	Median	All	0.491	0.893	.001	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM181A–SARC (OS)

Open the SARC breakdown →